Peter Grell MD· @GrellMd · X·· 14 小时前评分70
正文 · 原文
Standing ovation at #ESMO26! 👏
Practice-changing Phase 3 results from DeLLphi-305 (LBA3) for maintenance tarlatamab + durvalumab in 1L ES-SCLC: mOS: 21.1 vs 12.7 mo (HR 0.42; p < 0.001)
A new standard of care with BiTE + ICI💥
22 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Peter Grell MD · x.com